UPDATE: Janney Capital Markets Initiates Coverage on Impax Laboratories as The Last Mid-Cap Generics Company Standing

In a report published Wednesday, Janney Capital Markets analyst Jim Molloy initiated coverage on Impax Laboratories (NASDAQ: IPXL ) with a Buy rating and $30.00 price target. In the report, Janney Capital Markets noted, “We are initiating coverage of Impax Laboratories (IPXL) with a BUY rating and $30 fair value.